Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial – AstraZeneca September 22, 2023
Pfizer’s Talzenna snags broader prostate cancer nod than AstraZeneca and Merck’s rival PARP med – FiercePharma June 21, 2023
AstraZeneca dives into regulatory T cell therapies in deal with Quell Therapeutics – Endpoints News June 9, 2023
AstraZeneca pays $85M to Quell Type 1 diabetes with ‘one and done’ cell therapy – FierceBiotech June 9, 2023
AstraZeneca: Tagrisso-chemo combo improved progression-free survival in late-stage lung cancer trial – Endpoints News – Endpoints News May 17, 2023
Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial – AstraZeneca May 17, 2023
Nearly 600,000 course of Pfizer’s Paxlovid are sitting UNUSED in America April 15, 2022April 14, 2022